**Article:**
BriaCell Therapeutics Corp., a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, has released new imaging data from its Phase 2 study. The images demonstrate regression and resolution of metastatic breast cancer tumors in patients with involvement in the eye orbit, temporal lobe of the brain, liver, and spine. These findings provide visual evidence of tumor response to BriaCell’s investigational therapies.
Previously, the company reported survival outcomes for these patients and others in similar study populations. The new images complement those data by illustrating the extent of tumor shrinkage and immune system activation observed during treatment. BriaCell continues to advance its clinical programs aimed at improving outcomes for patients with advanced breast cancer.
**Why this matters**
Metastatic breast cancer is challenging to treat, especially when it spreads to critical organs such as the brain and liver. Visual confirmation of tumor regression supports the potential effectiveness of BriaCell’s immunotherapy approach. These results contribute to ongoing efforts to develop new treatment options that can extend survival and improve quality of life for patients with advanced cancer.
Source: NewsData